Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATHENA trial of ziltivekimab in inflammatory HFmrEF/HFpEF
2023-506988-34-00Phase 3Authorised
- Sponsor
- Novo Nordisk
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF) and chronic inflammation comparing ziltivekimab with placebo (2 arms). Primary endpoint: Change in Kansas City Cardiomyopathy Questionnaire clinical summary score. Planned start Mar 2024; status: authorised.
02
Drugs
ziltivekimab
03
Conditions
heart failure with preserved ejection fraction (HFpEF)chronic inflammation
Beyond the preview
Go deeper on 2023-506988-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506988-34-00.